Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions Signs an Option to Exclusive License Agreement with the University at Buffalo to Develop Novel Monoclonal Antibody Targeting a Multiligand Receptor Involved in Inflammatory Responses and Cancer

New York, NY, May 27, 2020 – Manhattan BioSolutions, Inc. (MBS), a biotechnology company focused on the discovery of the next-generation therapies […]

Published May 22, 2023

Manhattan BioSolutions, Inc. Selected to be Featured in New York Pavilion at BIO International Convention

https://www.issuewire.com/manhattan-biosolutions-inc-selected-to-be-featured-in-new-york-pavilion-at-bio-international-convention-1766550010501619 New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of […]

Published February 16, 2024

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

Published May 12, 2020

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers […]

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University